Another test is often done around the eight-week mark to confirm that the treatment has successfully corrected the deficiency
989-1002, Duncan, Jessica, et al
Is the essential reconstitution and dilution solvent for research-grade lyophilised peptides, recombinant proteins, and biological research compounds available to laboratories in Ireland and a sterile, non-pyrogenic aqueous solution containing 0.9% w/v benzyl alcohol as a bacteriostatic preservative that inhibits microbial growth in reconstituted peptide solutions, enabling multiple-use vial access over extended periods while maintaining sterility between uses
Serious safety concerns (immune reactions, cancer risk)
Fluid recommendations must be individualized when edema, heart failure or advanced kidney disease is present
Warnings and Precautions Hypokalemia: B12 therapy may cause a drop in potassium levels (hypokalemia), particularly during early treatment in patients with significant B12 deficiency